16 https://hadea.ec.europa.eu ORG-0001 Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency COV2, Place Charles Rogier 16 HADEA - Directorate of HaDEA,HADEA.A - Health and Food,HADEA.A.2 - EU4Health/SMP Food Brussels B-1210 BE100 BEL HADEA +32 2 299 11 11 hadea-procurement@ec.europa.eu http://curia.europa.eu ORG-0002 Court of Justice of the European Union Rue du Fort Niedergrünewald Luxembourg L-2925 LU000 LUX CURIA +352 4303-1 GC.Registry@curia.europa.eu https://commission.europa.eu/ ORG-0003 European Commission Mondrian (CDMA), Rue du Champ de Mars 21 Brussels B-1050 BE100 BEL EUCOM +32 2 299 11 11 hadea-procurement@ec.europa.eu 00381062-2026105/20262026-06-03+02:00 2.3 eforms-sdk-1.14 b066e5d1-16b6-4a5b-8385-b6e21020dea8 a41196e2-a5b3-443e-88a5-425ab8f1cc7d 2026-06-02+02:00 10:14:44+02:00 01 32024R2509 cn-standard ENG eu-ins-bod-ag gen-pub ORG-0001 ted-esen ORG-0003 epo-procurement-document For the full list of exclusion grounds please consult the procurement documents. open false HADEA/2026/OP/0019 Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Ebola Sudan (SUDV), Ebola Bundibugyo (BDBV) and/or Marburg (MARV), which – in case of an outbreak – could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development. Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority). services In case of unavailability or disruptions in the functioning of the electronic means of communication provided in Section 5.1.11 in the last 5 calendar days before the time limit for receipt indicated in Section 5.1.12, the contracting authority reserves the right to extend this time limit and publish the extension at the Internet address provided in Section 5.1.11, without a preceding publication of a corrigendum to this notice. Economic operators interested in this procurement are invited to subscribe to the call for tenders at the address in Section 5.1.11 in order to get notified when new information or documents are published. true 16000000 73100000 Please consult the procurement documents. anyw-eea LOT-0001 EU4HEALTH eu-funds default-text non-restricted-document ENG official https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/a41196e2-a5b3-443e-88a5-425ab8f1cc7d-CN?#anchorDocuments epo-procurement-document none no allowed not-allowed per-exa 80 quality Please consult the procurement documents. per-exa 20 price Please consult the procurement documents. https://webgate.ec.europa.eu/digit/opsys/esubmission?cftUuid=a41196e2-a5b3-443e-88a5-425ab8f1cc7d 6 ORG-0001 ORG-0002 BUL CES DAN DEU ELL ENG SPA EST FIN FRA GLE HRV HUN ITA LIT LAV MLT NLD POL POR RON SLK SLV SWE true true Funding and Tenders Portal required false https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/a41196e2-a5b3-443e-88a5-425ab8f1cc7d-CN?#anchorDocuments 2026-09-02+02:00 16:00:59+02:00 2026-08-25+02:00 23:59:59+02:00 202663-2026 2026-09-04+02:00 10:00:00+02:00 false none none HADEA/2026/OP/0019 Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Ebola Sudan (SUDV), Ebola Bundibugyo (BDBV) and/or Marburg (MARV), which – in case of an outbreak – could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development. Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority). services 16000000 73100000 73120000 Please consult the procurement documents. anyw-eea 48